Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;108(1):104-115.
doi: 10.1007/s00223-020-00659-6. Epub 2020 Jan 22.

Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

Nobuaki Ito  1 , Seiji Fukumoto  2
Affiliations
Review

Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

Nobuaki Ito et al. Calcif Tissue Int. 2021 Jan.

Abstract

Congenital diseases that could result in hyperphosphatemia at an early age include hyperphosphatemic familial tumoral calcinosis (HFTC)/hyperostosis-hyperphosphatemia syndrome (HHS) and congenital hypoparathyroidism/pseudohypoparathyroidism due to the insufficient activity of fibroblast growth factor (FGF) 23 and parathyroid hormone. HFTC/HHS is a rare autosomal recessive disease caused by inactivating mutations in the FGF23, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3), or Klotho (KL) genes, resulting in the excessive cleavage of active intact FGF23 (FGF23, GALNT3) or increased resistance to the action of FGF23 (KL). Massive ectopic calcification, known as tumoral calcinosis (TC), is seen in periarticular soft tissues, typically in the hip, elbow, and shoulder in HFTC/HHS, reducing the range of motion. However, other regions, such as the eye, intestine, vasculature, and testis, are also targets of ectopic calcification. The other symptoms of HFTC/HHS are painful hyperostosis of the lower legs, dental abnormalities, and systemic inflammation. Low phosphate diets, phosphate binders, and phosphaturic reagents such as acetazolamide are the treatment options for HFTC/HHS and have various consequences, which warrant the development of novel therapeutics involving recombinant FGF23.

Keywords: FGF23; FGF23-related hyperphosphatemia; GALNT3; Klotho; Tumoral calcinosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chakhtoura M et al (2018) Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature. Osteoporos Int 29(9):1987–2009 - PubMed - DOI - PMC
    1. Al-Azem H, Khan AA (2012) Hypoparathyroidism. Best Pract Res Clin Endocrinol Metab 26(4):517–522 - PubMed - DOI
    1. Kilav R, Silver J, Naveh-Many T (1995) Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 96(1):327–333 - PubMed - PMC - DOI
    1. Slatopolsky E et al (1996) Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97(11):2534–2540 - PubMed - PMC - DOI
    1. Pfister MF et al (1998) Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci USA 95(4):1909–1914 - PubMed - DOI

Publication types

Substances

LinkOut - more resources